



Vaccine Adjuvants

Take your vaccine to the next level

InVivoGen



Corrections

J Immunol 2010; 184:1121; ;
doi: 10.4049/jimmunol.0990112
<http://www.jimmunol.org/content/184/2/1121>

This information is current as
of May 17, 2021.

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2010 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Corrections

Li, X., T. Shiratsuchi, G. Chen, P. Dellabona, G. Casorati, R. W. Franck, and M. Tsuji. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. *J. Immunol.* 183: 4415–4421.

In Fig. 4A, the unit of measurement for the concentration of glycolipids and IC50 was incorrectly stated as nM. The unit of measurement should be μ M.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0990112